A Long-Term, Open-label Extension Study of F2695 SR in Adult Patients With Major Depressive Disorder.

Trial Profile

A Long-Term, Open-label Extension Study of F2695 SR in Adult Patients With Major Depressive Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2013

At a glance

  • Drugs Levomilnacipran (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Registrational
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 19 May 2013 Results will be presented at the American Psychiatric Association (APA) annual meeting, according to a Forest Laboratories media release.
    • 18 Jul 2012 Actual end date (June 2012) added as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top